Teva, Starbucks, Malibu Media: Intellectual Property

Teva Pharmaceutical Industries Ltd. lost a bid to block approval of a generic form of Copaxone, a multiple sclerosis drug that may account for half the company’s profit, 10 days before the patent on the medication expires.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.